OakChart

Zenas Biopharma Inc

ZBIOHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 3:59 PM ET

28.70+0.12 (0.42%)
2026-11-12 05:51 CET
Market cap
1,946.37 USD m
Revenue, TTM
11.00 USD m
Net income, TTM
-541.81 USD m
Free cash flow, TTM
-242.83 USD m
EPS diluted, TTM
-10.04
P/E
-
Compare

Price

ZBIO against its 20, 50 and 200-day averages
2050200beatmiss
20.0025.0030.0035.001.7M3.5MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26ZBIOclose 28.7020-day 27.6650-day 28.79200-day 25.2828.70

35.7% under the 52-week high of 44.60 on 24 Dec 2025. 52-week low 13.50 on 5 Jan 2026. Last 15 sessions, 16.4% high to low

Volume 0.46× normal · the line is the 50-bar volume average

Profile

ZBIO
52-week range, 49% of the way up
13.5044.60

Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.

IndexRUT
Employees167
IPOSep 13, 2024
Beta-0.82
ATR, 14d1.85
Rel volume0.46
Short float37.39%
Insider own55.22%
Inst own73.82%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap1.95B
Enterprise Value1.76B
Income-541.81M
Sales11.00M
Book/sh3.13
Cash/sh8.63
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees167
IPOSep 13, 2024

Ratios

P/E-
Forward P/E-
PEG-
P/S176.94
P/B9.16
P/C3.33
P/FCF-
EV/EBITDA-
EV/Sales160.10
Quick Ratio9.42
Current Ratio9.42
Debt/Eq1.88
LT Debt/Eq1.88
Option/ShortYes / Yes

Earnings

EPS (ttm)-10.04
EPS next Y-5.47
EPS next Q-1.17
EPS this Y27.84%
EPS next Y10.20%
EPS next 5Y22.47%
EPS past 3/5Y-39.47% -
Sales past 3/5Y- -
EPS Y/Y TTM-121.60%
Sales Y/Y TTM-26.67%
EPS Q/Q-34.81%
Sales Q/Q-
EarningsNov 05 BMO
EPS/Sales Surpr.-32.78% -

Ownership

Insider Own55.22%
Insider Trans0.16%
Inst Own73.82%
Inst Trans21.66%
ROA-108.66%
ROE-265.11%
ROIC-88.65%
Gross Margin99.78%
Oper. Margin-2747.55%
Profit Margin-4925.53%
SMA203.75%
SMA50-0.31%
SMA20013.55%
Trades-

Technical

Shs Outstand67.80M
Shs Float30.37M
Short Float37.39%
Short Ratio17.17
Short Interest11.35M
52W High44.60 -35.65%
52W Low13.50 112.59%
Volatility7.69% 6.88%
ATR (14)1.85
RSI (14)53.36
Beta-0.82
Rel Volume0.46
Avg Volume661.17K
Volume305,770

Performance

Perf Week0.84%
Perf Month14.07%
Perf Quarter-1.71%
Perf Half Y44.00%
Perf YTD-20.96%
Perf Year-18.47%
Perf 3Y-
Perf 5Y-
Perf 10Y-
Recom1.25
Target Price47.88
Prev Close28.58
Price28.70
Change %0.42%

Analyst ratings

latest 10 of 10
DateActionAnalystRating changeTargetImplied
Oct 20, 2026ResumedMMorgan StanleyEqual-Weight$32+11.5%
Jan 05, 2026DowngradeMMorgan StanleyOverweight → Equal-Weight$19-33.8%
Mar 20, 2025InitiatedWWedbushOutperform$35+22.0%
Feb 04, 2025InitiatedWWolfe ResearchOutperform$19-33.8%
Dec 16, 2024InitiatedHH.C. WainwrightBuy$30+4.5%
Nov 05, 2024InitiatedRRodman & RenshawBuy$34+18.5%
Oct 08, 2024InitiatedMMorgan StanleyOverweight$40+39.4%
Oct 08, 2024InitiatedJJefferiesBuy$35+22.0%
Oct 08, 2024InitiatedGGuggenheimBuy$45+56.8%
Oct 08, 2024InitiatedCCitigroupBuy$27-5.9%

Peers

Mkt cap
TickerCompanyMkt cap
CLYMClimb Bio Inc719.55M
IMVTImmunovant Inc7.67B
VERAVera Therapeutics Inc2.20B
DNTHDianthus Therapeutics Inc5.03B
VRDNViridian Therapeutics Inc3.55B
CABACabaletta Bio Inc312.79M
ANABAnaptysBio Inc1.46B
ARGXArgen X SE ADR61.48B
KYTXKyverna Therapeutics Inc316.63M
ZURAZura Bio Ltd137.75M

Insider trading

latest 14 of 16
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Zebra Aggregator, LPAffiliateAug 19 '26Proposed Sale31.911,000,00031,910,000Aug 19 04:15 PM
MOULDER LEON O JRChief Executive OfficerMay 18 '26Buy16.8860,0001,012,80096,928May 18 09:12 PM
MOULDER LEON O JRChief Executive OfficerApr 29 '26Buy17.6235,000616,7001,786,039Apr 29 07:21 PM
MOULDER LEON O JRChief Executive OfficerApr 28 '26Buy18.0225,000450,5001,751,039Apr 29 07:21 PM
Lu HongboDirectorMar 31 '26Buy18.633,76870,198426,736Apr 02 05:02 PM
Fairmount Funds Management LLCDirectorMar 31 '26Buy20.00150,0003,000,0002,359,025Apr 01 04:30 PM
MOULDER LEON O JRChief Executive OfficerMar 31 '26Buy19.3134,000656,5401,726,039Mar 31 08:14 PM
MOULDER LEON O JRChief Executive OfficerMar 30 '26Buy18.2320,000364,6001,692,039Mar 31 08:14 PM
Lu HongboDirectorMar 31 '26Buy20.0075,0001,500,000422,968Mar 31 05:00 PM
Lu HongboDirectorFeb 11 '26Buy22.5025,985584,662347,968Feb 13 05:35 PM
Allen Patricia LDirectorFeb 12 '26Buy24.8515,700390,08815,700Feb 13 05:06 PM
Allen Patricia LDirectorFeb 13 '26Buy26.364,160109,65819,860Feb 13 05:06 PM
MOULDER LEON O JRChief Executive OfficerFeb 02 '26Buy17.9657,0001,023,720423,155Feb 03 04:30 PM
MOULDER LEON O JRChief Executive OfficerJan 07 '26Buy16.3850,000819,000316,155Jan 09 09:42 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
IBBiShares Biotechnology ETFAUM: 11.36B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
FYCFirst Trust Small Cap Growth AlphaDEX FundAUM: 1.35B
IWCiShares Micro-Cap ETFAUM: 1.22B

News

latest 14 of 172
  • Zenas BioPharma to Present at the Jefferies London Global Healthcare Conference (GlobeNewswire)
  • Zenas BioPharma Reports Third Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire) -8.89%
  • Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.53%
  • Zenas BioPharma Announces the Presentation of New Obexelimab Data in IgG4-Related Disease at the 6th International Symposium on IgG4-Related Disease (GlobeNewswire)
  • Zenas BioPharma Announces Upcoming Presentations of Orelabrutinib Data in Relapsing Remitting Multiple Sclerosis, Clinical Trial Designs in Progressive Multiple Sclerosis and Other Multiple Sclerosis Portfolio Data at MSToronto2026 (GlobeNewswire)
  • Zenas BioPharma to Host Virtual R&D Event (GlobeNewswire)
  • Zenas BioPharma Announces Upcoming Presentations of Obexelimab Data in IgG4-Related Disease at the IgG4ward! 6th International Symposium on IgG4-Related Disease and ACR Convergence 2026 (GlobeNewswire)
  • Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
  • Zenas BioPharma to Host Obexelimab IgG4-RD Investor Event (GlobeNewswire)
  • Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences (GlobeNewswire)
  • Fortune Brands and 4 More Stocks See Action From Activist Investors (Barrons.com)
  • Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
  • Zenas BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire) -6.68%
  • Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-05-1.650-1.243-1.65010.000.007
2026Q22026-08-13-1.770-1.122-1.7661.0015.007
2026Q12026-05-13-1.460-1.474-1.4560.000.007
2025Q42026-03-16-4.540-1.001-5.1720.0013.337
2025Q32025-11-12-1.220-1.038-1.2220.008.006
2025Q22025-08-12-1.250-1.038-1.2470.003.755
2025Q12025-05-15-0.800-1.134-0.80310.001.674
2024Q42025-02-26-2.108-0.990-1.2593.750.005
2024Q32024-11-12-5.020-0.951-0.9240.000.004
2024Q22024-08-28-6.205--0.9910.00--
2026Q4---1.167--11.267
2027Q1---1.353--0.004
2027Q2---1.223--25.004
2027Q3---1.358--4.204
2027Q4---1.408--16.134

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2024FY-11.891-6.513-3.7565.000.00
2025FY-8.440-4.121-8.44010.0018.00
2026FY--6.091--20.38
2027FY--5.470--51.62
2028FY--3.934--158.05
2029FY--2.060--366.47
2030FY--0.543--547.99

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-0550011.260.0056.30
2026Q4S2026-10-2750011.260.0056.30
2026Q4S2026-08-1350111.260.0056.30
2026Q4S2026-06-0251021.260.0056.30
2026Q4S2026-05-1450111.260.0056.30
2026Q4S2026-05-1350021.260.0056.30
2026Q4S2026-03-1650021.260.0056.30
2026Q4S2026-02-2830035.430.0056.30
2026Q4S2025-12-1531035.430.0056.30
2026Q4S2025-11-2030018.770.0056.30
2026Q4S2025-11-1240014.080.0056.30
2026Q4S2025-11-112000.000.000.00
2026Q4S2025-11-102000.000.000.00
2026Q4S2025-11-092000.000.000.00

Estimate history

EPS, annual-3.113-0.969-3.756-8.445-10.0401
Period2022202320242025TTM
EPS, quarterly-0.924-1.259-0.803-1.247-1.222-5.172-1.456-1.766-1.647
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual05051011
Period2022202320242025TTM
Sales, quarterly05100000110
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual38.31738.31741.79354.48667.795
Period2022202320242025MRQ
Shares, quarterly41.78141.79341.82242.08942.21354.48662.38363.33167.795
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY
Total Revenue11.0010.005.0050.000.00
Cost of Goods Sold Incl. D&A0.020.060.140.110.08
Gross Profit10.989.944.8649.89-0.08
Selling, General and Administrative Excl. Other313.21221.33168.7577.0375.12
Research and Development237.55168.06139.1460.0361.61
Other Operating Expense0.000.000.000.000.00
Operating Income-302.23-211.38-163.89-27.15-75.20
Interest Expense35.487.330.00--
Unusual Expense224.17171.670.8510.3044.14
Net Income Before Taxes-541.54-377.82-156.56-36.82-119.28
Income Taxes0.27-0.080.430.300.00
Consolidated Net Income-541.81-377.74-156.99-37.12-119.28
Net Income From Continuing Operations-541.81-377.74-156.99-37.12-119.28
Net Income-541.81-377.74-156.99-37.12-119.28
EPS (Recurring)-5.82-5.76-3.74-0.78-2.31
EPS (Basic, Before Extraordinaries)-10.04-8.44-3.76-0.97-3.11
EPS (Diluted)-10.04-8.44-3.76-0.97-3.11
EBITDA-302.21-211.33-163.75-27.03-75.12
Non-Operating Income (Expense)20.3412.578.180.620.06
Other After Tax Adjustments0.000.000.000.000.00
Stock Option Compensation Expense35.6420.818.55--
Price To Sales Ratio162.18162.4168.46--
Gross Margin99.7899.4497.2699.77-
Operating Margin-2,747.55-2,113.85-3,277.76-54.29-
Net Margin-4,925.53-3,777.37-3,139.76-74.25-
Shares Outstanding67.8054.4941.7938.3238.32
Market Capitalization1,946.371,946.37501.37501.37-

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue10.001.000.000.000.000.0010.005.00
Cost of Goods Sold Incl. D&A0.000.000.010.010.010.010.020.03
Gross Profit10.001.00-0.01-0.01-0.01-0.019.984.97
Selling, General and Administrative Excl. Other85.9178.6677.3471.3047.5755.1547.3160.59
Research and Development58.4762.9160.4455.7234.4043.0334.9149.16
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-75.91-77.66-77.35-71.31-47.58-55.16-37.33-55.62
Interest Expense11.2210.306.637.330.000.000.000.00
Unusual Expense27.5030.000.00166.675.000.000.00-
Net Income Before Taxes-108.87-111.34-80.99-240.34-51.50-52.20-33.78-52.17
Income Taxes0.050.110.000.110.000.02-0.200.43
Consolidated Net Income-108.92-111.46-80.99-240.44-51.50-52.22-33.57-52.60
Net Income From Continuing Operations-108.92-111.46-80.99-240.44-51.50-52.22-33.57-52.60
Net Income-108.92-111.46-80.99-240.44-51.50-52.22-33.57-52.60
EPS (Recurring)-1.36-1.43-1.46-2.66-1.14-1.25-0.80-1.26
EPS (Basic, Before Extraordinaries)-1.65-1.77-1.46-5.17-1.22-1.25-0.80-1.26
EPS (Diluted)-1.65-1.77-1.46-5.17-1.22-1.25-0.80-1.26
EBITDA-75.91-77.66-77.34-71.30-47.57-55.15-37.31-55.59
Non-Operating Income (Expense)5.756.622.994.971.082.963.553.45
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense13.656.819.205.995.804.784.254.34
Price To Sales Ratio162.181,601.79-168.8262.4027.0522.0268.46
Gross Margin99.9699.60----99.7799.34
Operating Margin-759.09-7,765.90-----373.30-1,112.46
Net Margin-1,089.23-11,145.60-----335.73-1,052.08
Shares Outstanding67.8063.3362.3854.4942.2142.0941.8241.79
Market Capitalization1,946.371,602.331,121.411,949.09934.85405.37330.15501.37

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY
Cash & Short Term Investments343.19350.8656.8667.21
Short Term Receivables0.000.000.000.00
Inventories0.000.000.000.00
Other Current Assets7.985.072.951.24
Total Current Assets351.17355.9259.8068.44
Net Property, Plant & Equipment1.391.191.011.80
Total Investments and Advances17.270.000.090.09
Other Assets13.8112.867.284.25
Total Assets383.64369.9768.1874.58
Short Term Debt Incl. Current Port. of LT Debt1.110.790.560.71
Accounts Payable7.1117.145.405.82
Income Tax Payable0.120.21--
Other Current Liabilities54.3039.1617.3119.44
Total Current Liabilities62.6557.2923.2625.97
Long Term Debt78.850.2220.560.81
Provision for Risks Charges0.000.000.000.00
Other Liabilities0.000.000.000.00
Total Liabilities141.5057.5143.8126.78
Non-Equity Reserves0.000.000.000.00
Preferred Stock - Carrying Value0.000.00250.09240.09
Common Equity242.14312.46-225.72-192.29
Total Shareholders Equity242.14312.4624.3647.80
Accumulated Minority Interest0.000.000.000.00
Total Equity242.14312.4624.3647.80
Total Liabilities & Stockholders Equity383.64369.9768.1874.58
Book Value Per Share4.447.48-5.89-5.02
Tangible Book Value Per Share4.447.48-5.89-5.02
Full-Time Employees167130--
Price to Book Ratio9.161.391.39-
Return on Assets-100.25-71.66-52.01-
Return on Equity-136.22-93.22-102.89-
Return on Invested Capital-117.68-50.21-82.64-245.38
Quick Ratio5.616.212.572.64
Current Ratio5.616.212.572.64

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY
Net Income-541.81-377.74-156.99-37.12-119.28
Depreciation0.020.060.140.110.08
Other Funds (Non Cash)295.37204.4011.7514.5245.59
Funds from Operations-246.42-173.28-145.10-22.49-73.62
Extraordinary Item0.000.000.000.000.00
Changes in Working Capital3.590.9525.43-8.047.97
Cash from Operating Activities-242.83-172.33-119.67-30.53-65.65
Capital Expenditures-0.00-0.02-0.13-0.02-2.20
Net Assets From Acquisitions0.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.00
Purchase or Sale of Investments-281.16-216.87-30.420.000.00
Purchase of Investments-678.73-417.75-36.420.000.00
Sale Or Maturity of Investments397.56200.896.000.000.00
Other Uses-87.50-35.000.000.000.00
Other Sources0.000.000.000.000.00
Cash from Investing Activities-368.67-251.89-30.55-0.02-2.20
Cash Dividends Paid0.000.000.000.000.00
Change in Capital Stock388.28152.94412.960.1259.39
Repurchase of Common Pref Stock0.000.000.000.000.00
Sale of Common Pref Stock388.28152.94412.960.1259.39
Proceedsfrom Stock Options376.41148.85412.680.0059.39
Issuance or Reduction of Debt, Net294.650.000.0020.000.00
Change in Long Term Debt294.650.000.0020.000.00
Issuance of Long Term Debt294.650.000.0020.000.00
Reduction of Long Term Debt0.000.000.000.000.00
Net Financing Active Other Cash Flow-9.3462.340.000.000.00
Other Financing Activities Uses-9.34-12.660.000.000.00
Cash from Financing Activities673.59215.28412.9620.1259.39
Exchange Rate Effect0.12-0.250.160.08-0.04
Net Change in Cash62.21-209.19262.89-10.35-8.50
Free Cash Flow-242.83-172.35-119.81-30.55-65.85
Preferred Dividends (Cash Flow)-0.000.00--
Deferred Taxes & Investment Tax Credit-0.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments585.31643.13717.21343.19290.88273.28
Short Term Receivables0.000.801.100.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets18.149.8711.867.985.765.32
Total Current Assets603.45653.79730.16351.17296.64278.60
Net Property, Plant & Equipment1.600.841.121.390.861.07
Total Investments and Advances61.7730.761.3417.2710.721.61
Intangible Assets0.00-----
Other Assets8.3916.2915.0613.8113.8011.80
Total Assets675.22701.69747.68383.64322.02293.08
Short Term Debt Incl. Current Port. of LT Debt1.220.821.041.110.620.79
Accounts Payable7.067.598.947.116.447.93
Income Tax Payable0.050.000.120.120.000.00
Other Current Liabilities55.7257.4151.0654.3045.3644.52
Total Current Liabilities64.0465.8261.1662.6552.4253.24
Long Term Debt398.87388.77350.6978.850.180.21
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.0072.990.00
Total Liabilities462.91454.59411.85141.50125.5953.46
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity212.31247.10335.83242.14196.43239.63
Total Shareholders Equity212.31247.10335.83242.14196.43239.63
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity212.31247.10335.83242.14196.43239.63
Total Liabilities & Stockholders Equity675.22701.69747.68383.64322.02293.08
Book Value Per Share3.133.905.384.444.655.69
Tangible Book Value Per Share3.133.905.384.444.655.69
Full-Time Employees---167--
Price to Book Ratio9.164.714.407.803.901.43
Return on Assets-108.66-97.39-78.63-100.25-52.35-71.80
Return on Equity-265.11-199.04-137.11-136.22-68.33-88.40
Return on Invested Capital-17.82-17.53-11.80-74.91-26.19-21.77
Quick Ratio9.429.9311.945.615.665.23
Current Ratio9.429.9311.945.615.665.23

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-108.92-111.46-80.99-240.44-51.50-52.22
Depreciation0.000.000.010.010.010.01
Other Funds (Non Cash)53.2446.7715.65179.7014.035.31
Funds from Operations-55.67-64.68-65.33-60.73-37.46-46.90
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-2.317.44-9.868.31-3.665.16
Cash from Operating Activities-57.98-57.24-75.20-52.41-41.12-41.74
Capital Expenditures-0.000.00-0.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments8.29-257.7031.61-63.3645.04-112.29
Purchase of Investments-137.50-331.81-76.52-132.89-59.20-126.55
Sale Or Maturity of Investments145.8074.11108.1369.53104.2414.26
Other Uses-27.50-30.000.00-30.00-5.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-19.21-287.7031.61-93.3640.04-112.29
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock57.2314.42166.45150.180.941.72
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock57.2314.42166.45150.180.941.72
Proceedsfrom Stock Options48.7313.61165.49148.570.280.00
Issuance or Reduction of Debt, Net-0.0227.64267.030.000.000.00
Change in Long Term Debt-0.0227.64267.030.000.000.00
Issuance of Long Term Debt-1.9529.57267.030.000.000.00
Reduction of Long Term Debt1.93-1.930.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.00-9.3471.680.00
Other Financing Activities Uses0.000.000.00-9.34-3.320.00
Cash from Financing Activities57.2142.06433.48140.8472.621.72
Exchange Rate Effect1.18-0.76-0.310.010.03-0.24
Net Change in Cash-18.80-303.65389.58-4.9271.56-152.55
Free Cash Flow-57.98-57.24-75.20-52.41-41.12-41.74

Revenue breakdown

Pharmaceutical Preparations2024: 5.00M 2025: 10.00M
United States2024: 5.00M 2025: 10.00M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3037.39%11.4M30.4M644.72K
2026-10-1542.95%12.5M29.2M711.53K
2026-09-3036.07%11.9M33.1M761.09K
2026-09-1535.85%11.9M33.1M839.50K
2026-08-3134.29%11.7M34.1M842.03K
2026-08-1434.87%11.7M33.4M805.76K
2026-07-3133.89%11.8M34.7M794.66K
2026-07-1535.09%12.2M34.7M726.52K
2026-06-3035.17%12.2M34.7M731.76K
2026-06-1532.10%11.1M34.7M703.54K
2026-05-2934.20%10.9M31.8M668.76K
2026-05-1533.60%10.7M31.8M696.95K
2026-04-3041.91%10.9M25.9M770.79K
2026-04-1539.38%10.2M26.0M797.18K
2026-03-3137.14%9.4M25.2M997.28K
2026-03-1330.58%7.7M25.2M846.09K
2026-02-2734.01%8.0M23.6M820.92K
2026-02-1333.07%7.8M23.6M755.95K
2026-01-3030.16%6.6M21.8M669.36K
2026-01-1527.88%6.1M21.8M691.62K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.5024.5028.500.0028.5140.000.000.997-0.0190.000
call5.0022.0026.000.0014.2520.000.000.995-0.0200.001
call7.5019.5023.500.0010.5330.000.000.966-0.3230.003
call10.0017.0021.000.008.3570.000.000.936-0.4020.006
call12.5014.5018.500.007.4790.000.000.906-0.4330.007
call15.0012.0016.000.006.1830.000.000.875-0.4400.009
call17.509.5013.500.005.1230.000.000.842-0.4340.011
call20.007.0011.506.304.2141.000.000.803-0.4160.012
call22.504.509.005.003.4063.000.000.759-0.3900.014
call25.002.556.204.102.4624.002.000.704-0.3530.015
call30.000.004.301.982.7179.000.000.538-0.2630.018
call35.000.004.900.053.5968.000.000.471-0.3630.018
call40.000.004.900.004.4110.000.000.462-0.4470.018
call45.000.004.900.004.9370.000.000.438-0.4970.018
put2.500.000.050.006.9730.000.00-0.003-0.0170.000
put5.000.000.050.004.9360.000.00-0.005-0.0180.001
put7.500.004.900.0016.6070.000.00-0.034-0.3160.003
put10.000.004.900.0012.6840.000.00-0.064-0.4010.006
put12.500.004.900.0010.2280.000.00-0.094-0.4310.007
put15.000.004.902.468.4660.000.00-0.125-0.4380.009
put17.500.004.900.007.1700.000.00-0.153-0.4300.011
put20.000.004.900.005.9350.000.00-0.196-0.4140.012
put22.500.004.901.004.9341.000.00-0.241-0.3870.014
put25.000.004.901.454.0310.000.00-0.296-0.3510.015
put30.000.604.902.752.3391.000.00-0.462-0.2600.018
put35.004.008.500.002.4110.000.00-0.529-0.3590.018
put40.009.0013.000.002.7100.000.00-0.568-0.4180.018
put45.0014.0018.000.003.1900.000.00-0.592-0.4640.017

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-068-KCurrent report2026-11-06SEC
2026-11-06424B5SEC
2026-11-05SCHEDULE 13G/ASEC
2026-11-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-058-KCurrent report2026-11-05SEC
2026-10-27SCHEDULE 13GSEC
2026-10-138-KCurrent report2026-10-12SEC
2026-09-11S-3ASRAutomatic shelf registration statement of securities of well-known seasoned issuersSEC
2026-09-11S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-09-083Initial statement of beneficial ownership of securities2026-08-26SEC
2026-09-08SCHEDULE 13G/ASEC
2026-09-08SCHEDULE 13GSEC
2026-09-024Statement of changes in beneficial ownership of securities2026-09-01SEC
2026-09-023Initial statement of beneficial ownership of securities2026-09-01SEC
2026-08-19144Filing for proposed sale of securities under Rule 144.SEC
2026-08-19SCHEDULE 13D/ASEC
2026-08-17SCHEDULE 13D/ASEC
2026-08-1310-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-138-KCurrent report2026-08-12SEC
2026-06-174Statement of changes in beneficial ownership of securities2026-06-15SEC
2026-06-174Statement of changes in beneficial ownership of securities2026-06-15SEC
2026-06-174Statement of changes in beneficial ownership of securities2026-06-15SEC
2026-06-174Statement of changes in beneficial ownership of securities2026-06-15SEC
2026-06-174Statement of changes in beneficial ownership of securities2026-06-15SEC
2026-06-174Statement of changes in beneficial ownership of securities2026-06-15SEC
2026-06-174Statement of changes in beneficial ownership of securities2026-06-15SEC
2026-06-174Statement of changes in beneficial ownership of securities2026-06-15SEC
2026-06-174Statement of changes in beneficial ownership of securities2026-06-15SEC
2026-06-174Statement of changes in beneficial ownership of securities2026-06-15SEC
2026-05-184Statement of changes in beneficial ownership of securities2026-05-18SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-051.01M100
2026-041.07M200
2026-035.59M500
2026-022.11M400
2026-011.64M300
2025-120000
2025-110000

Institutional holders

Manager% owned
FMR LLC15.03%
SR ONE CAPITAL MANAGEMENT, LP7.98%
NEA Management Company, LLC6.37%
Enavate Sciences GP, LLC6.21%
FEDERATED HERMES, INC.4.94%
BlackRock, Inc.4.25%
Capital International Investors3.96%
Polar Capital Holdings Plc3.82%
Royalty Pharma Sub-Manager, LLC3.78%
Fairmount Funds Management LLC3.74%

Funds

Fund% owned
VANGUARD HEALTH CARE FUND4.65%
SMALLCAP World Fund Inc3.86%
State Street(R) SPDR(R) S&P(R) Biotech ETF2.14%
Federated Hermes Kaufmann Fund2.11%
Strategic Advisers Fidelity U.S. Total Stock Fund1.63%
VANGUARD TOTAL STOCK MARKET INDEX FUND1.41%
iShares Russell 2000 ETF1.18%
Fidelity Stock Selector Small Cap Fund1.05%
Fidelity Small Cap Growth K6 Fund0.84%
Fidelity Advisor Health Care Fund0.79%

OakChart. ZBIO. Cached 15 minutes.